The cocktail of antibodies from the Swiss pharmaceutical group Roche developed with the American laboratory Regeneron for mild to moderate forms of Covid-19 has been approved in Japan, the company said in a press release.
Japan is the first country in the world to approve this treatment, which has elsewhere received emergency or temporary authorizations in the face of the urgent health situation.
Symptoms reduced by four days
Known as REGEN-COV in the United States, but called Ronapreve in other countries, this treatment which combines the drugs casirivimab and imdevimab has obtained authorization from the Japanese Ministry of Health on the basis of phase studies III who have shown that this drug combination reduces hospitalizations and deaths by 70%.
Conducted with non-hospitalized high-risk patients, these clinical trials also demonstrated a four-day reduction in the duration of symptoms, Roche said in the press release.
Approval in Japan was obtained following a special procedure for emergency situations.
Active treatment against variants
The clearance "brings hope to patients in Japan who can now access this important treatment option," Levi Garraway, Roche's chief medical officer, said in the statement.
“In addition, its ability to remain active against emerging variants, including the Delta variant, has been demonstrated in pre-clinical studies,” he added.
Roche, the world number one in oncology, joined forces with the American giant Regeneron in August to develop, manufacture and distribute this dual therapy outside the United States, instructing it to take care of the approval procedures outside the ground American.
Coronavirus: The Institut Pasteur de Lille will begin clinical trials of its treatment
Coronavirus: A promising arthritis drug against severe forms of Covid